This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Post #30 is the version of this I will quote in future. One addition.
Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.
The thing about tirzepatide in type 2 diabetes that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to look, not a result.
On purity: the trailing-edge features people report on tirzepatide chromatograms are frequently deamidation products, which elute close to the main peak and are easy to integrate into it. That is a method question rather than a quality question.
This is the version I would want a new member to read first.
Answering the question post #32 raises rather than the one it answers.
Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose swing is slightly larger. Most people do not report noticing the difference in practical terms.
Where I part company with post #32, and it is a narrow parting.
Adding a small correction to the tirzepatide in type 2 diabetes summary above rather than a disagreement with it. The substance holds; one of the figures is out by a factor that matters.
What I want from this tirzepatide in type 2 diabetes thread is the list of things that would need to be true for the claim to hold. If we can write that list, we can check it.
Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.
A qualification I should have led with rather than closed on.
Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose swing is slightly larger. Most people do not report noticing the difference in practical terms.
Written in the hope of being told what I have missed.
Post #36 and I disagree about the size of the effect, not about the direction.
Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.
Worth separating two things that post #42 runs together.
I disagree with the framing of tirzepatide in type 2 diabetes above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be checked.
The reasoning depends on an assumption that is doing a lot of work and is never stated. If the assumption holds, the conclusion follows. I do not think it holds generally.
This follows post #42 rather than contradicting it.
Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a finer gradation. That does not mean you cannot escalate on a coarser schedule if that suits you — the published schedule is not a lower bound.
Practical note on tirzepatide in type 2 diabetes: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow.
SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose. That is the central and legitimate criticism of the head-to-head evidence and it is worth remembering when people quote the trial.
I am confident about the direction and much less about the magnitude.
Taking post #45 at face value and following it one step further.
Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that the question is not settled. Some of the effect is surely the GIP component, but the trial design does not decompose it.
I had written a reply contradicting post #45 and deleted it. Here is what survived.
Before the thread moves on from tirzepatide in type 2 diabetes — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.
Confirming post #49 from a second method, which matters more than confirming it from a second person.
On purity: the trailing-edge features people report on tirzepatide chromatograms are frequently deamidation products, which elute close to the main peak and are easy to integrate into it. That is a method question rather than a quality question.
Genuinely open to being wrong about this one.
Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.
That is my reading. Someone else read the same page differently and was reasonable.
Mass and charge states: tirzepatide is about 4813.5 Da and on an electrospray instrument you would expect to see charge states mostly in the 2+ to 4+ range, the same as semaglutide. A doubly charged species would appear at about (4813.5 + 2 × 1.008) / 2 ≈ 2408.
Worth checking against a second source before it gets quoted onward.
Comparisons between the tirzepatide and semaglutide programmes across trials rather than within one are weak. Different populations, different durations, different baseline characteristics; the only fair comparison is a head-to-head one.
Happy to expand any of that if it is the useful part.
Post #50 and I disagree about the size of the effect, not about the direction.
I have three months of notes on tirzepatide in type 2 diabetes and the honest summary is that the trend is real and the week-to-week numbers are noise. I nearly drew the opposite conclusion from the first fortnight.
Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly comparable in character. Individual variation is the largest factor.
That is the practical version. The rigorous version is longer and says the same thing.
Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted preparations in different diluents have not been studied and extrapolation from the licensed formulation is the best you can do.
Posting it because the silence on this was starting to look like agreement.
Building on post #56 rather than restating it.
Where the tirzepatide in type 2 diabetes discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same sentence with different clothes on.
Confirming post #56 from a second method, which matters more than confirming it from a second person.
Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.
Reading it again, the caveat matters more than the finding.
I had written a reply contradicting post #59 and deleted it. Here is what survived.
SURPASS-2's comparator choice is the criticism that survives. Semaglutide 1.0 mg was the licensed diabetes dose at the time and it was not the highest dose available in the class, so the trial answers a narrower question than the headline implies.